


## MACROECONOMIC INDICES

### Inflation

According to Federal State Statistics Service's data, the Consumer Price Index was estimated at 100.7% in January 2021 as compared to the previous month,

In January of 2021, Industrial Producer Price Index (for goods intended for sale on the domestic market) was 103.5%, whereas in the month-earlier period it had amounted to 101.5%.

**Figure 1. Consumer Price Index (compared with the previous period)**




### Living standard

In December 2020, a gross monthly average wage of corporate employees reached RUB 51083 (USD 689.84). It accounted for 109.7% compared to December of 2019, and 140.7% compared to the previous period. In December 2020, the real gross wage accounted for 104.6% as compared to December of 2019, and 139.5% against the prior period. According to estimates<sup>1</sup>, real disposable cash incomes decreased by 3.0% in 2020 compared to 2019 (Fig. 2).

### Retail turnover

In January 2021, the retail turnover was equal to RUR 2803.7 bil. or 99.9% (at comparable prices) as compared to January of the previous year (Fig. 2).

**Figure 2. Real wage and retail turnover**



\* 2020 vs 2019

### Industrial Production

According to Federal State Statistics Service's data, Industrial Production Index accounted for 97.5% in January 2021 as compared to the same period in the previous year, and 78.9% as compared to December 2020.

According to Federal State Statistics Service's data, Industrial Production Index of drugs and medical products in January 2021 accounted for 174.9% compared to the relevant period of 2020, and 58.6% as compared to December of 2020.

### Domestic production

Table 1 provides the top 10 domestic pharmaceutical manufacturers according to their volumes of sales in all segments of the market based on the results for January 2021.

**Table 1. The top ten Russian chemical and pharmaceutical manufacturers by sales volume in January 2021.**

Rank	Manufacturer	RUB mil.
1	Otcpharm	3460.7
2	Stada	1954.3
3	R-Pharm	1938.9
4	Biocad	1529.2
5	Pharmstandart	1377.2
6	Valenta	1074.0
7	Akrihin	1023.3
8	Promomed	979.1
9	Vertex	954.9
10	Grotex	920.4

Source - Remedium according to IQVIA data

Table 2 provides pharmacy sales data from 10 regions of the Russian Federation. Sales (in terms of roubles) increased in eight regions in December 2020 as compared to the previous month. The most pronounced growth in sales was observed in Moscow (+28%), the least one in Tyumen (+0.3%). Tatarstan (-5%) and Novosibirsk region (-11%) showed reduction in sales.

**Table 2. Pharmacy sales in the regions, 2020**

Region	Pharmacy sales, \$ mil. (wholesale prices)			Growth gain, % (roubles)		
	October 2020	November 2020	December 2020	October/September 20	November/October 20	December/November 20
Moscow	160.7	160.3	212.7	-7%	-1%	28%
St. Petersburg	72.5	73.6	94.2	-13%	1%	23%
Krasnodar Krai	49.0	47.5	57.7	15%	-4%	17%
Krasnoyarsk Krai	27.6	29.8	31.2	15%	7%	1%
Tatarstan	27.5	25.8	25.4	12%	-7%	-5%
Rostov Region	33.0	28.4	34.8	22%	-15%	18%
Novosibirsk Region	29.4	30.3	28.0	23%	2%	-11%
Voronezh Region	18.6	16.4	17.4	31%	-12%	2%
Perm	10.3	10.0	11.0	32%	-4%	5%
Tyumen	9.7	9.6	10.0	15%	-1%	0.3%

### Advertising

The largest advertisers and pharmaceutical brand names highly publicized in mass media (TV, radio, press, outdoor advertising) are shown in Tables 3 & 4.

**Table 3. Top five advertisers in mass media in January 2021**

Rank	Company*	Quantity of broadcasts
1	Otcpharm	12,648
2	Johnson & Johnson	10,712
3	GSK Consumer Healthcare	9,371
4	Sanofi	8,970
5	Bayer	8,250

Source - Remedium according to Mediascope's data

**Table 4. Top five trade names in mass media in January 2021**

Rank	Brand*	Quantity of broadcasts
1	Strepsils	3,745
2	Otrivin	3,439
3	Nurofen	3,012
4	Evalar	2,550
5	Pentalgin	2,542

Source - Remedium according to Mediascope's data

\* Only drugs registered with National Medicine Register were considered.


<sup>1</sup> Due to switching of Federal State Statistics Service to the updated methodology for calculating real disposable cash incomes of the population, the data are published once a quarter.

## RUSSIAN PHARMACY FPP DRUG MARKET: 2020 RESULTS

According to the results of the Retail Audit of FPP (Finished Pharmaceutical Products) in Russian Federation™, at year-end 2020 the sales of drugs in natural terms in the country saw a 1% increase to 4.686 bil. packs compared to 2019. In money terms, the market saw a 10% increase in terms of roubles and 1% decrease in terms of dollars. The volume of the market amounted to RUB 938.727 bil (USD 13.015 bil.) at wholesale prices (Fig. 1).

The average cost of an OTC pack at retail prices proved to be lower than the previous year figure: USD 3.39 in 2020 vs USD 3.48 in 2019. At year-end 2020, consumer spending for drugs in Russia averaged to USD 108.28, whereas during the same period a year ago it averaged to USD 110.25.

**Figure 1. All-Russia pharmacy market in 2019 – 2020**



BAYER (+7%) managed to hold its leading positions in terms of sales among manufacturers on the Russian pharmacy market (Table 1). The most dynamic among the leaders OTCPHARM (+45%) that moved up to this rank from rank six was ranked second. In addition, the other two drug manufacturers moved up to yet higher ranks. SANDOZ (+22%) moved up two points and ABBOTT (+9%) moved up one point, coming in at numbers five and nine, respectively. Concurrently due to low growth rates SANOFI (+5%), STADA (+1%) and BERLIN-CHEMIE/MENARINI (+4%) lost one point each, and TEVA and SERVIER (+3% each) lost two points each. In total, the top ten manufacturers accumulated 34.4% of the Russian retail market, as in the year-earlier period.

**Table 1. The top ten drug manufacturers by pharmacy sales**

Rank in the top ten	2020	2019	Manufacturer*	Share in total pharmacy sales, %	
				2020	2019
1	1		<b>BAYER</b>	4.6	4.7
2	6		OTCPHARM	4.1	3.1
3	2		<b>SANOFI</b>	3.9	4.1
4	3		<b>STADA</b>	3.6	3.9
5	7		<b>SANDOZ</b>	3.4	3.0
6	4		TEVA	3.2	3.5
7	5		<b>SERVIER</b>	3.2	3.4
8	8		KRKA	2.9	3.0
9	10		<b>ABBOTT</b>	2.8	2.8
10	9		<b>BERLIN-CHEMIE/MENARINI</b>	2.7	2.8
Total				34.4	34.4

\*AIPM members are in bold

XARELTO (+21%) remained the best-selling brand in the regional market (Table 2). Newcomers, antiviral drugs INGAVIRIN (2.5-fold growth in sales) and ARBIDOL (4.9-growth), as well anti-coagulant ELIQUIS (+59%) broke into the top ten ranking, moving up to ranks two through four. At the same time, they displaced the less dynamic brands NUROFEN (+5%), DETRALEX and CONCOR (+2% each), as well as MEXIDOL (+3%) three ranks down. MIRAMISTIN (+21%) and PENTALGIN (+18%) held their previous bottom ranks in the top ten. The total share of the top 10 increased from 6.1% to 7.7%.

**Table 2. The top ten brands by pharmacy sales**

Rank in the top ten	2020	2019	Brand	Share in total pharmacy sales, %	
				2020	2019
1	1		XARELTO	1.2	1.1
2	13		INGAVIRIN	1.1	0.5
3	45		ARBIDOL	1.1	0.2
4	12		ELIQUIS	0.7	0.5
5	2		NUROFEN	0.7	0.7
6	3		DETRALEX	0.7	0.7
7	4		CONCOR	0.6	0.7
8	5		MEXIDOL	0.6	0.6
9	9		MIRAMISTIN	0.6	0.5

<sup>2</sup>Hereinafter, unless otherwise stated, growth gains are stated in the rouble equivalent or national currency.

Rank in the top ten		Brand	Share in total pharmacy sales, %	
2020	2019		2020	2019
10	10	PENTALGIN	0.6	0.5
Total			7.7	6.1

The leader of the top ten INN and group names ranking also managed to hold its own in the ranking. Despite its zero sales rates and reduction of the market share, XYLOMETAZOLINE (+0.4%) held its previous rank one (Table 3). Some shifts took place in the lower part of the top-10 ranking. Due to 4.5-fold growth in sales, UMIFENOVIR moved up to rank two from the fifth ten, RIVAROXABAN (+21%) moved up to rank three from four, and another newcomer IMIDAZOLYL ETHANAMIDE PENTANDIOIC ACID (2.5-fold growth) broke into the top ten ranking, coming in at rank five. In contrast, the remaining six INNs fell in the ranks: IBUPROFEN (+6%), DIOSMIN\*HESPERIDIN (+4%), BISOPROLOL and PANCREATIN (+5% each), as well as NIMESULIDE (+14%) and DICLOFENAC (+11%). The total share of the top-ten INNs and grouping names increased from 9.2% to 10.5%.

**Table 3. The top 10 INNs and grouping names by pharmacy sales**

Rank	2020	2019	INNs/Grouping Names	Share in total pharmacy sales, %	
				2020	2019
1	1		XYLOMETAZOLINE	1.4	1.6
2	47		UMIFENOVIR	1.2	0.3
3	4		RIVAROXABAN	1.2	1.1
4	30		IMIDAZOLYL ETHANAMIDE PENTANDIOIC ACID	1.1	0.5
5	3		IBUPROFEN	1.0	1.1
6	2		DIOSMIN*HESPERIDIN	1.0	1.1
7	5		BISOPROLOL	1.0	1.0
8	6		PANCREATIN	0.9	1.0
9	7		NIMESULIDE	0.9	0.9
10	9		DICLOFENAC	0.8	0.8
Total				10.5	9.2

As in the previous rankings, the leader of the top ten ATC groups held its own in the ranking: C09 Agents acting on the renin-angiotensin system (+13%) continued to lead the top ten ranking (Table 4). J05 Antivirals for systemic use (+96%) that moved up to this rank from rank nine due to the highest growth rates among the leaders ranked second in terms of sales. The markets of the other four ATC groups developed at a fast pace. J01 Antibacterials for systemic use (+34%) moved up to rank four, whereas B1 Antithrombotic agents (+19%), N02 Analgesics (+15%) and R05 Cough and cold preparations (+1%) moved down to ranks five, eight and nine.

M01 Anti-inflammatory and antirheumatic drugs (+6%) lost one rank, while G03 Sex hormones (-0.1%) and R01 Nasal preparations (-1%) reduced their sales and moved two ranks down, coming in at ranks six and seven. C05 Vasoprotectives (+5%) held their previous rank ten. In total, the top ten ATC groups accumulated 38.9%, whereas the year-earlier period they accounted for 36.4%.

**Table 4. The top ten ATC Groups by pharmacy sales**


Rank	2020	2019	ATC code	ATC group	Share in total pharmacy sales, %	
					2020	2019
1	1		C09	AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM	5.4	5.2
2	9		J05	ANTIVIRALS FOR SYSTEMIC USE	5.1	2.9
3	2		M01	ANTINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS	4.8	4.9
4	6		J01	ANTIBACTERIALS FOR SYST USE	4.2	3.4
5	3		B01	ANTITHROMBOTIC AGENTS	4.1	3.8
6	4		G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM	3.3	3.7
7	5		R01	NASAL PREPARATIONS	3.3	3.7
8	7		N02	ANALGESICS	3.2	3.1
9	8		R05	COUGH AND COLD PREPARATIONS	2.9	2.9
10	10		C05	VASOPROTECTIVES	2.7	2.8
Total					38.9	36.4

**Conclusion.** Based on the results for 2020, the retail pharmacy market of the country brought in RUB 1146.1 bil. (USD 15.890 bil.). The growth was positive in terms of roubles (+9%), but negative (-2%) in terms of dollars as compared to 2019. In pack terms, the market showed slight positive growth rates (+1%) as compared to 2019 and amounted to 4.686 bil. packs. In 2020, the average cost of an FPP pack in the national pharmacies was USD 3.39, whereas in the year-earlier period it was USD 3.48. The average expenses of the Russian Federation residents for purchase of OTC drugs in pharmacies reduced as compared to the previous year (USD 108.28 vs. USD 110.25).

## RUSSIAN FEDERATION HOSPITAL MARKET: 2020 RESULTS

According to the results of the Budget Audit of FPPs in the Russian Federation (without DLO and regional benefit)™, the national hospital market based on the results for 2020 reduced by 5% in physical terms and amounted to 626.245 mil. packs. In value terms, the market showed a 37% increase in terms of roubles and 21% in terms of dollars and reached RUB 352.719 bil. (USD 4.834 mil.) at wholesale prices. Based on the results for 2020, the average cost of an FPP pack in the hospital sector of the Russian Federation was USD 7.72, whereas in the year-earlier period its cost was USD 6.09.

**Figure 1. All-Russia pharmacy market in 2019 – 2020**



Due to 69% growth in purchases, ROCHE became the leader of the top ten manufacturers in the Russian hospital market at year-end 2020 (Table 1). MSD (+51%) held and reinforced its previous rank two. BIOCAD (+29%), which had topped the rating earlier, but was not so dynamic rounded out the top three drug manufacturers ranking. In addition to the first two, the markets of BRISTOL MYERS (+99%) and JOHNSON & JOHNSON (+61%) developed at a faster pace, which allowed them to move up to ranks four and eight, respectively. Note that the latter has become the only newcomer of the top 10 rating. The rest of the manufacturers showed low dynamics, and at the same time four of them fell in the ranks. PFIZER (+25%), PHARMASYNTEZ (+22%), MICROGEN (+22%) and NOVARTIS (+9%) moved down to ranks five, seven and two bottom ranks, respectively. SANOFI (+35%) reserved its rank six. The total share of the top 10 brands increased from 41.7% to 44.0%.

**Table 1. The top 10 drug manufacturers by hospital purchases**

Rank in the top ten	Manufacturer*	Share in total hospital purchases, %	
		2020	2019
1	<b>ROCHE</b>	6.9	4.8
2	<b>MSD</b>	6.3	5.7
3	<b>BIOCAD RF</b>	6.2	6.6
4	<b>BRISTOL MYERS SQU</b>	4.5	3.1
5	<b>PFIZER</b>	4.0	4.4
6	<b>SANOFI</b>	3.6	3.7
7	<b>PHARMASYNTEZ</b>	3.4	3.8
8	<b>JOHNSON &amp; JOHNSON</b>	3.4	2.9
9	<b>MICROGEN</b>	3.2	3.6
10	<b>NOVARTIS</b>	2.4	3.1
Total		44.0	41.7

\*AIPM members are in bold

Just as in the previous ranking, the top three brands from the top ten brands ranking did not change in composition, however the allocation of positions changed (Table 2). OPDIVO (2-fold growth in purchases) and KEYTRUDA (+95%) moved up one rank, coming in at the first two ranks, displacing SOVIGRIPP (+38%) from rank one to three. The markets of the other five brands also developed at a fast pace. AVEGRA (+50%), PERJETA (+61%) and the newcomer ULTRIX (4.6-growth in purchases) moved up to ranks four through six, respectively. The second newcomer, KADCYLA (+89%) rounded out the top 10 ranking. Due to a 73% increase in purchases, another brand TIVICAY moved up two ranks, to number eight. At the same time, PREVENAR (+7%) and HERTICAD (+4%) showed low sales rates and moved down to ranks seven and nine, respectively. The total share of the top 10 brands in the hospital market expanded from 18.7% to 22.4%.

**Table 2. The top 10 brands by hospital purchases**

Rank in the top ten	Brand	Share in total hospital purchases, %	
		2020	2019
1	OPDIVO	3.7	2.5
2	KEYTRUDA	3.4	2.4
3	SOVIGRIPP	2.6	2.5
4	AVEGRA BIOCAD	2.4	2.2
5	PERJETA	1.9	1.6
6	ULTRIX	1.8	0.5

Rank in the top ten		Brand	Share in total hospital purchases, %	
2020	2019		2020	2019
7	4	PREVENAR 13	1.8	2.3
8	10	TIVICAY	1.7	1.3
9	6	HERTICAD	1.6	2.1
10	13	KADCYLA	1.6	1.1
Total			22.4	18.7

INN VACCINE, INFLUENZA (+46%) maintained and strengthened its leadership in the top ten INN and group names ranking (Table 3). It should be noted that most of the INNs of this rating, just like the leader, demonstrated outstripping sales growth. INN NIVOLUMAB that moved to rank two has doubled its growth. PEMBROLIZUMAB (+95%), BEVACIZUMAB (+44%) and PERTUZUMAB (+61%) moved up to ranks three, four and six, and three newcomers FAVIPIRAVIR, DOLUTEGRAVIR (+73%) and TRASTUZUMAB EMTANSINE (+89%) rounded out the top ten ranking. And only TRASTUZUMAB (+14%) and VACCINE, PNEUMOCOCCAL CONJUGATE (+14%) moved down to ranks five and seven, respectively. The total share accumulated by the top-ten INNs and grouping names increased from 20.6% to 25.1%.

**Table 3. The top 10 INNs and grouping names by hospital purchases**

Rank	INNs/Grouping Names	Share in total hospital purchases, %	
		9 mon. 2020	9 mon. 2019
1	VACCINE, INFLUENZA	4.7	4.4
2	NIVOLUMAB	3.7	2.5
3	PEMBROLIZUMAB	3.4	2.4
4	BEVACIZUMAB	2.5	2.4
5	TRASTUZUMAB	2.2	2.6
6	PERTUZUMAB	1.9	1.6
7	VACCINE, PNEUMOCOCCAL CONJUGATE	1.8	2.3
8	FAVIPIRAVIR	1.8	0.0
9	DOLUTEGRAVIR	1.7	1.3
10	TRASTUZUMAB EMTANSINE	1.6	1.1
Total		25.1	20.6

One newcomer broke into the top ten ATC groups ranking: J06 Immune sera and immunoglobulins (+15%) moved up to rank ten from 12 (Table 4). Three more groups managed to improve their ranks: J05 Antivirals for systemic use (+51%), B01 Antithrombotic agents (+88%) and L04 Immunosuppressants (2.9 growth in purchases) moved up to ranks two, five and six. The leader of the ranking L01 Antineoplastic agents (+43%) held its previous rank one and J01 Antibacterials for systemic use (+81%) and L02 Endocrine therapy (+47%) retained their previous ranks four and eight. The less dynamic J07 Vaccines (+25%), B05 Plasma substitution and perfusion solutions (+10%) and V08 Contrast media (+8%) moved down to ranks three, seven and nine, respectively. In total, the top ten ATC groups accumulated 81.6% of the hospital market, whereas in the year-earlier period - 76.1%.

**Table 4. The top ten ATC groups by hospital purchases**

Rank	ATC code	ATC group	Share in total hospital purchases, %	
			2020	2019
1	L01	ANTINEOPLASTIC AGENTS	32.3	31.0
2	J05	ANTIVIRALS FOR SYSTEMIC USE	12.2	11.1
3	J07	VACCINES	10.6	11.7
4	J01	ANTIBACTERIALS FOR SYST USE	8.1	6.1
5	B01	ANTITHROMBOTIC AGENTS	4.8	3.5
6	L04	IMMUNOSUPPRESSANTS	4.5	2.1
7	B05	PLASMA SUBSTITUTES AND PERFUSION SOLUTIONS	3.7	4.6
8	L02	ENDOCRINE THERAPY	2.4	2.2
9	V08	CONTRAST MEDIA	1.7	2.3
10	J06	IMMUNE SERA & IMMUNOGLOBULIN	1.3	1.6
Total			81.6	76.1

**Conclusion.** At year-end 2020, the Russian hospital market was positive both in rouble terms (+37%) and in dollar terms (+21%). Its volume amounted to RUB 352.719 bil. (USD 4.834 bil.). In pack terms, the market reduced by 5% and amounted to 626.245 mil. packs. At year-end 2020, the average cost of a finished pharma product (FPP) pack in the Russian hospital sector amounted to USD 7.72 vs. USD 6.09 in the year earlier period.

**PHARMACEUTICAL MARKET OF THE CENTRAL FEDERAL DISTRICT (CFD) IN 2021 KEY PERFORMANCE INDICATORS**


**Macroeconomic indices**

**Table 1: Recent statistical data on socio-economic situation in CFD**

Value	December-January 2020	December-January 2020 (%) vs. December-January 2019
Industrial production index		105.1
Retail turnover, RUB bil.	11,711.1	96.8
Monthly average accrued wage per worker (nominal), RUB	65,188	106.7
real		103.4


Note: CFD TOGS data

**Figure 1. Movement of price index and non-food product price index vs December 2019**




**Indicators of movement of price and retail margins**

**Figure 1. Movement of weighted average prices and retail margins in 2019-2020**




**Figure 2. Movement of weighted average purchase prices in 2019–2020**




**Indicators of the market movement and profile<sup>3</sup>**


**Figure 3. CFD pharmaceutical market in 2019–2020**




**Figure 4. Structure of CFD pharmaceutical market by major segments in 2019–2020**



**Figure 5. Retail segment pattern of the CFD market in 2019–2020**



**Figure 6. Movement of the Russian/foreign drugs share in the CFD pharmaceutical market pattern in 2019–2020**



<sup>3</sup> Exclusive of Moscow

**PHARMACEUTICAL MARKET OF THE NORTH-WESTERN FEDERAL DISTRICT (NWFD) IN 2020 KEY PERFORMANCE INDICATORS**


**Macroeconomic indices**

**Table 1: Recent statistical data on socio-economic situation in NWFD**

Value	December-January 2020	December-January 2020 (%) vs. December-January 2019
Industrial production index		97.0
Retail turnover, RUB bil.	3,394.2	99.5
Monthly average accrued wage per worker (nominal), RUB	56,827	104.5
real		101.0


Note: NWFD TOGS data

**Figure 1. Movement of price index and non-food product price index vs December 2019**




**Indicators of movement of price and retail margins**

**Figure 1. Movement of weighted average prices and retail margins in 2019-2020**




**Figure 2. Movement of weighted average purchase prices in 2019– 2020**




**Indicators of the market movement and profile<sup>4</sup>**


**Figure 3. CFD pharmaceutical market in 2019– 2020**




**Figure 4. Major segment pattern of the NWFD pharmaceutical market in 2019– 2020**



**Figure 5. Retail segment pattern of the NWFD market in 2019– 2020**



**Figure 6. Movement of the Russian/foreign drugs share in the NWFD pharmaceutical market pattern in 2019– 2020**



<sup>4</sup> Exclusive of St. Petersburg

**PHARMACEUTICAL MARKET OF THE VOLGA FEDERAL DISTRICT (VFD) IN 2020 KEY PERFORMANCE INDICATORS**


**Macroeconomic indices**

**Table 1: Recent statistical data on socio - economic situation in VFD**

Value	December-January 2020	December-January 2020 (%) vs. December-January 2019
Industrial production index		96.6
Retail turnover, RUB bil.	5,767.4	95.2
Monthly average accrued wage per worker (nominal), RUB	36,811	105.5
real		102.0


Note: VFD TOGS data

**Figure 1. Movement of price index and non-food product price index vs December 2019**




**Indicators of movement of price and retail margins**

**Figure 1. Movement of weighted average prices and retail margins in 2019-2020**




**Figure 2. Movement of weighted average purchase prices in 2019– 2020**




**Indicators of the market movement and profile**


**Figure 3. VFD pharmaceutical market in 2019– 2020**




**Figure 4. Major segment pattern of the VFD pharmaceutical market in 2019– 2020**



**Figure 5. Retail segment pattern of the VFD market in 2019– 2020**



**Figure 6. Movement of the Russian/foreign drugs share in the VFD pharmaceutical market pattern in 2019– 2020**



**PHARMACEUTICAL MARKET OF THE URAL FEDERAL DISTRICT (UFD) IN 2020 KEY PERFORMANCE INDICATORS**


**Macroeconomic indices**

**Table 1: Recent statistical data on socio-economic situation in UrFD**

Value	December-January 2020	December-January 2020 (%) vs. December-January 2019
Industrial production index		97.7
Retail turnover, RUB bil.	2,808.2	95.6
Monthly average accrued wage per worker (nominal), RUB	54,155	105.6
real		102.5


Note: VFD TOGS data

**Figure 1. Movement of price index and non-food product price index vs December 2019**




**Indicators of movement of price and retail margins**

**Figure 1. Movement of weighted average prices and retail margins in 2019-2020**




**Figure 2. Movement of weighted average purchase prices in 2019– 2020**




**Indicators of the market movement and profile**


**Figure 3. UrFD pharmaceutical market in 2019– 2020**




**Figure 4. Major segment pattern of the UrFD pharmaceutical market in 2019– 2020**



**Figure 5. Retail segment pattern of the UrFD market in 2019– 2020**



**Figure 6. Movement of the Russian/foreign drugs share in the VFD pharmaceutical market pattern in 2019– 2020**



**PHARMACEUTICAL MARKET OF THE SIBERIAN FEDERAL DISTRICT (SFD) IN 2020 KEY PERFORMANCE INDICATORS**


**Macroeconomic indices**

**Table 1: Recent statistical data on socio-economic situation in SiFD**

Value	December-January 2020	December-January 2020 (%) vs. December-January 2019
Industrial production index		95.6
Retail turnover, RUB bil.	2,915.6	95.7
Monthly average accrued wage per worker (nominal), RUB	43,897	106.3
real		102.7


Note: SiFD TOGS data

**Figure 1. Movement of price index and non-food product price index vs December 2019**




**Indicators of movement of price and retail margins**

**Figure 1. Movement of weighted average prices and retail margins in 2019-2020**




**Figure 2. Movement of weighted average purchase prices in 2019– 2020**




**Indicators of the market movement and profile**


**Figure 3. SiFD pharmaceutical market in 2019– 2020**




**Figure 4. Major segment pattern of the Siberian FD pharmaceutical market in 2019– 2020**



**Figure 5. Retail segment pattern of the Siberian FD market in 2019– 2020**



**Figure 6. Movement of the Russian/foreign drugs share in the Siberian FD pharmaceutical market pattern in 2019– 2020**





**PHARMACEUTICAL MARKET OF THE SOUTHERN FEDERAL DISTRICT (SoFD) IN 2020 KEY PERFORMANCE INDICATORS**


**Macroeconomic indices**

**Table 1: Recent statistical data on socio-economic situation in SoFD**

Value	December-January 2020	December-January 2020 (%) vs. December-January 2019
Industrial production index		99.0
Retail turnover, RUB bil.	3,459.8	95.6
Monthly average accrued wage per worker (nominal), RUB	36,166	104.2
real		100.9


Note: SoFD TOGS data

**Figure 1. Movement of price index and non-food product price index vs December 2019**




**Indicators of movement of price and retail margins**

**Figure 1. Movement of weighted average prices and retail margins in 2019-2020**




**Figure 2. Movement of weighted average purchase prices in 2019–2020**




**Indicators of the market movement and profile**


**Figure 3. SoFD pharmaceutical market in 2019–2020**




**Figure 4. Major segment pattern of the SoFD pharmaceutical market in 2019–2020**



**Figure 5. Retail segment pattern of the Southern FD market in 2019–2020**



**Figure 6. Movement of the Russian/foreign drugs share in the SoFD pharmaceutical market pattern in 2019–2020**



**PHARMACEUTICAL MARKET OF THE FAR EASTERN FEDERAL DISTRICT (FEFD) IN 2020 KEY PERFORMANCE INDICATORS**


**Macroeconomic indices**

**Table 1: Recent statistical data on socio - economic situation in FEFD**

Value	December-January 2020	December-January 2020 (%) vs. December-January 2019
Industrial production index		95.9
Retail turnover, RUB bil.	1,891.6	96.6
Monthly average accrued wage per worker (nominal), RUB	59,863	105.4
real		101.4


Note: FEFD TOGS data

**Figure 1. Movement of price index and non-food product price index vs December 2019**




**Indicators of movement of price and retail margins**

**Figure 1. Movement of weighted average prices and retail margins in 2019-2020**




**Figure 2. Movement of weighted average purchase prices in 2019– 2020**




**Indicators of the market movement and profile**


**Figure 3. FEFD pharmaceutical market in 2019– 2020**



**Figure 4. Major segment pattern of the FEFD pharmaceutical market in 2019– 2020**



**Figure 5. Retail segment pattern of the FEFD market in 2019– 2020**



**Figure 6. Movement of the Russian/foreign drugs share in the FEFD pharmaceutical market pattern in 2019– 2020**

